BACKGROUND: Liver stiffness measurement (LSM) can assess liver fibrosis in patients with chronic hepatitis B (CHB). We evaluated whether LSM can be used to assess changes in liver fibrosis during antiviral treatment using nucleos(t)ide analogs in patients with CHB. METHODS: We recruited 41 patients with CHB who had significant liver fibrosis, normal or slightly elevated serum alanine aminotransferase (ALT) levels (≤2 × upper limit of normal), and detectable serum hepatitis B virus DNA before antiviral treatment. Patients in Group 1 (n = 23) and Group 2 (n = 18) underwent follow-up LSM after antiviral treatment for 1 and 2 years, respectively. RESULTS: The mean age, ALT and LSM value of all patients (34 men and 7 women) before antiviral treatment were 46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa, respectively. Hepatitis B e antigen (HBeAg) was detected in 31 patients (75.6%). Fibrosis stage was F2 in 12 (29.3%), F3 in 6 (14.6%) and F4 in 23 (56.1%) patients. After antiviral treatment, LSM values and DNA positivity decreased significantly as compared to baseline (P = 0.018 and P < 0.001 in Group 1; P = 0.017 and P < 0.001 in Group 2, respectively), whereas ALT levels were unchanged (P = 0.063 in Group 1; P = 0.082 in Group 2). CONCLUSIONS: Our preliminary data suggest that LSM can be used to assess liver fibrosis regression after antiviral treatment using nucleos(t)ide analogs in patients with CHB.
BACKGROUND:Liver stiffness measurement (LSM) can assess liver fibrosis in patients with chronic hepatitis B (CHB). We evaluated whether LSM can be used to assess changes in liver fibrosis during antiviral treatment using nucleos(t)ide analogs in patients with CHB. METHODS: We recruited 41 patients with CHB who had significant liver fibrosis, normal or slightly elevated serum alanine aminotransferase (ALT) levels (≤2 × upper limit of normal), and detectable serum hepatitis B virus DNA before antiviral treatment. Patients in Group 1 (n = 23) and Group 2 (n = 18) underwent follow-up LSM after antiviral treatment for 1 and 2 years, respectively. RESULTS: The mean age, ALT and LSM value of all patients (34 men and 7 women) before antiviral treatment were 46.6 ± 9.5 years, 40.6 ± 17.2 IU/L and 12.9 ± 8.6 kPa, respectively. Hepatitis B e antigen (HBeAg) was detected in 31 patients (75.6%). Fibrosis stage was F2 in 12 (29.3%), F3 in 6 (14.6%) and F4 in 23 (56.1%) patients. After antiviral treatment, LSM values and DNA positivity decreased significantly as compared to baseline (P = 0.018 and P < 0.001 in Group 1; P = 0.017 and P < 0.001 in Group 2, respectively), whereas ALT levels were unchanged (P = 0.063 in Group 1; P = 0.082 in Group 2). CONCLUSIONS: Our preliminary data suggest that LSM can be used to assess liver fibrosis regression after antiviral treatment using nucleos(t)ide analogs in patients with CHB.
Authors: Do Young Kim; Seung Up Kim; Sang Hoon Ahn; Jun Yong Park; Jung Min Lee; Young Nyun Park; Ki Tae Yoon; Yong Han Paik; Kwan Sik Lee; Chae Yoon Chon; Kwang-Hyub Han Journal: Dig Dis Sci Date: 2008-11-13 Impact factor: 3.199
Authors: J Y Park; Y N Park; D Y Kim; Y H Paik; K S Lee; B S Moon; K-H Han; C Y Chon; S H Ahn Journal: J Viral Hepat Date: 2008-06-28 Impact factor: 3.728
Authors: Y O Kweon; Z D Goodman; J L Dienstag; E R Schiff; N A Brown; E Burchardt; R Schoonhoven; D A Brenner; M W Fried; E Burkhardt Journal: J Hepatol Date: 2001-12 Impact factor: 25.083
Authors: J Vergniol; J Foucher; L Castéra; P-H Bernard; R Tournan; E Terrebonne; E Chanteloup; W Merrouche; P Couzigou; V de Lédinghen Journal: J Viral Hepat Date: 2008-10-17 Impact factor: 3.728
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Seung Up Kim; Kwang-Hyub Han; Jun Yong Park; Sang Hoon Ahn; Moon Jae Chung; Chae Yoon Chon; Eun Hee Choi; Do Young Kim Journal: Liver Int Date: 2008-10-24 Impact factor: 5.828
Authors: Ki Tae Yoon; Sun Min Lim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon; Mong Cho; Jun Woo Lee; Seung Up Kim Journal: Dig Dis Sci Date: 2012-06 Impact factor: 3.199
Authors: Young Eun Chon; Jun Yong Park; Sung-Min Myoung; Kyu Sik Jung; Beom Kyung Kim; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han Journal: Am J Gastroenterol Date: 2017-04-04 Impact factor: 10.864